CARES-310, 2023 NCT03764293
camrelizumab based treatment (n=272) vs. sorafenib (n=271)
randomized controlled trial
camrelizumab and rivoceranib (=apatinib)
camrelizumab 200 mg intravenously every 2 weeks plus rivoceranib 250 mg orally once daily
sorafenib
sorafenib 400 mg orally twice daily
mHCC - 1st line (L1)
open label
95 centres across 13 countries
PFS median follow up 7.8 monthsOS IA1 median follow up 14.5 months